Applying transcriptomic and proteomic knowledge to Parkinson's disease drug discovery

Bibliography

• DAUER W, PRZEDBORSKI S: Parkinson's disease: mechanisms and models. Neuron (2003) 39(6):889-909.
   PubMed Web of Science ®Google Scholar
• JELLINGER KA: Recent developments in the pathology of Parkinson's disease. J. Neural Transm. Suppl. (2002) (62):347-376.
   PubMed Web of Science ®Google Scholar
• SPILLANTINI MG, SCHMIDT ML, LEE VM et al.: α-Synuclein in Lewy bodies. Nature (1997) 388(6645):839-840.
   PubMed Web of Science ®Google Scholar
• SCHAPIRA AH, COOPER JM, DEXTER D et al.: Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. (1990) 54(3):823-827.
   PubMed Web of Science ®Google Scholar
• MCNAUGHT KS, JENNER P: Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. (2001) 297(3):191-194.
   PubMed Web of Science ®Google Scholar
• GOTZ ME, KUNIG G, RIEDERER P, YOUDIM MB: Oxidative stress: free radical production in neural degeneration. Pharmacol. Ther. (1994) 63(1):37-122.
   PubMed Web of Science ®Google Scholar
• YOUDIM MBH, RIEDERER P: Understanding Parkinson's disease. The smoking gun is still missing, but growing evidence suggests highly reactive substances called free radicals are central players in this common neurological disorder. Sci. Am. (1997) 276(1):52-59.
   PubMedGoogle Scholar
• JENNER P, OLANOW CW: Oxidative stress and the pathogenesis of Parkinson's disease. Neurology (1996) 47(6 Suppl. 3):S161-S170.
   PubMed Web of Science ®Google Scholar
• VAN DER SCHYF CJ, GELDENHUYS WJ, YOUDIM MB: Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J. Neurochem. (2006) 99(4):1033-1048.
   PubMed Web of Science ®Google Scholar
• GRUNBLATT E, MANDEL S, JACOB-HIRSCH J et al.: Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. (2004) 111(12):1543-1573.
   PubMed Web of Science ®Google Scholar
• KAMURA T, KOEPP DM, CONRAD MN et al.: Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science (1999) 284(5414):657-661.
   PubMed Web of Science ®Google Scholar
• LIANI E, EYAL A, AVRAHAM E et al.: Ubiquitylation of synphilin-1 and α-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc. Natl. Acad. Sci. USA (2004) 101(15):5500-5505.
   PubMed Web of Science ®Google Scholar
• ZHANG J, GOODLETT DR: Proteomic approach to studying Parkinson's disease. Mol. Neurobiol. (2004) 29(3):271-288.
   PubMed Web of Science ®Google Scholar
• MEREDITH GE, HALLIDAY GM, TOTTERDELL S: A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat. Disord. (2004) 10(4):191-202.
   PubMed Web of Science ®Google Scholar
• EPSTEIN AC, GLEADLE JM, MCNEILL LA et al.: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 107(1):43-54.
   PubMed Web of Science ®Google Scholar
• OSTREROVA-GOLTS N, PETRUCELLI L, HARDY J et al.: The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. (2000) 20(16):6048-6054.
   PubMed Web of Science ®Google Scholar
• TURNBULL S, TABNER BJ, EL-AGNAF OM et al.: α-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med. (2001) 30(10):1163-1170.
   PubMed Web of Science ®Google Scholar
• MILLER RM, KISER GL, KAYSSER-KRANICH TM et al.: Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol. Dis. (2006) 21(2):305-313.
   PubMed Web of Science ®Google Scholar
• PALOP JJ, CHIN J, MUCKE L: A network dysfunction perspective on neurodegenerative diseases. Nature (2006) 443(7113):768-773.
   PubMed Web of Science ®Google Scholar
• MORAN LB, DUKE DC, DEPREZ M et al.: Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics (2006) 7(1):1-11.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, JAMES M, MIDDLETON FA, DAVIS RL: Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2005) 137(1):5-16.
   Google Scholar
• HAUSER MA, LI YJ, XU H et al.: Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch. Neurol. (2005) 62(6):917-921.
   PubMed Web of Science ®Google Scholar
• DUKE DC, MORAN LB, KALAITZAKIS ME et al.: Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics (2006) 7(3):139-148.
   PubMed Web of Science ®Google Scholar
• RAVINA BM, FAGAN SC, HART RG et al.: Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology (2003) 60(8):1234-1240.
   PubMed Web of Science ®Google Scholar
• YOUDIM MBH, GROSS A, FINBERG JPM: Rasagiline [N-Propargyl-1R(+)-aminoindant], A selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. (2001) 132:500-506.
   PubMed Web of Science ®Google Scholar
• RASCOL O, BROOKS DJ, MELAMED E et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet (2005) 365(9463):947-954.
   PubMed Web of Science ®Google Scholar
• GROUP PS: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. (2004) 61(4):561-566.
   PubMed Web of Science ®Google Scholar
• BIGLAN KM, SCHWID S, EBERLY S et al.: Rasagiline improves quality of life in patients with early Parkinson's disease. Mov. Disord. (2006) 21(5):616-623.
   PubMed Web of Science ®Google Scholar
• RABEY JM, SAGI I, HUBERMAN M et al.: Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol. (2000) 23(6):324-330.
   PubMed Web of Science ®Google Scholar
• STUDY GROUP: Early rasagiline therapy shows long-term benefit for Parkinson's disease. 9th International Congress of Parkinson's Disease and Movement Disorder. New Orleans, USA (2005).
   Google Scholar
• MARUYAMA W, YOUDIM MBH, NAOI M: Antiapoptotic properties of rasagiline, N-propargylamine-1 (R)-aminoindan, and its optical (S)-isomer, TV1022. Ann. NY Acad. Sci. (2001) 939:320-329.
   PubMed Web of Science ®Google Scholar
• MARUYAMA W, AKAO Y, YOUDIM MBH et al.: Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. (2001) 78:727-735.
   PubMed Web of Science ®Google Scholar
• AKAO Y, MARUYAMA W, SHIMIZU S et al.: Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and Rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. (2002) 82(4):913-923.
   PubMed Web of Science ®Google Scholar
• BLANDINI F, ARMENTERO MT, FANCELLU R, BLAUGRUND E, NAPPI G: Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol. (2004) 187(2):455-459.
   PubMed Web of Science ®Google Scholar
• KUPSCH A, SAUTTER J, GOTZ ME et al.: Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm. (2001) 108(8-9):985-1009.
   PubMed Web of Science ®Google Scholar
• BAR-AM O, WEINREB O, AMIT T, YOUDIM MB: Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. (2005) 19(13):1899-1901.
   PubMed Web of Science ®Google Scholar
• SAGI Y, MANDEL S, AMIT T, YOUDIM MB: Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. (2007) 25(1):35-44.
   PubMed Web of Science ®Google Scholar
• SEMKOVA I, WOLZ P, SCHILLING M, KRIEGLSTEIN J: Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur. J. Pharmacol. (1996) 315(1):19-30.
   PubMed Web of Science ®Google Scholar
• TATTON WG, CHALMERS-REDMAN RM, JU WJ et al.: Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. (2002) 301(2):753-764.
   PubMed Web of Science ®Google Scholar
• MARUYAMA W, NITTA A, SHAMOTO-NAGAI M et al.: N-propargyl-1(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem. Int. (2004) 44(6):393-400.
   PubMed Web of Science ®Google Scholar
• WEINREB O, BAR-AM O, AMIT T, CHILLAG-TALMOR O, YOUDIM MBH: Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. (2004) 18(12):1471-1473.
   PubMed Web of Science ®Google Scholar
• YOUDIM MB, BUCCAFUSCO JJ: Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. (2005) 26(1):27-35.
   PubMed Web of Science ®Google Scholar
• ZHENG H, WEINER LM, BAR-AM O et al.: Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. (2005) 13(3):773-783.
   PubMed Web of Science ®Google Scholar
• WEINSTOCK M, BEJAR C, WANG RH et al.: TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. (2000) 60(Suppl.):S157-S170.
   Google Scholar
• FURLAN R, KURNE A, BERGAMI A et al.: A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J. Neuroimmunol. (2004) 150(1-2):10-19.
   PubMed Web of Science ®Google Scholar
• CHABRIER PE, AUGUET M, SPINNEWYN B et al.: BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy. Proc. Natl. Acad. Sci. USA (1999) 96(19):10824-10829.
   PubMed Web of Science ®Google Scholar
• BEN-SHACHAR D, KAHANA N, KAMPEL V, WARSHAWSKY A, YOUDIM MBH: Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology (2004) 46(2):254-263.
   PubMed Web of Science ®Google Scholar
• SOFIC E, PAULUS W, JELLINGER K, RIEDERER P, YOUDIM MBH: Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. (1991) 56(3):978-982.
   PubMed Web of Science ®Google Scholar
• RIEDERER P, SOFIC E, RAUSCH WD et al.: Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. (1989) 52(2):515-520.
   PubMed Web of Science ®Google Scholar
• BERG D: In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage. J. Neural Transm. (2006) 113(6):775-780.
   PubMed Web of Science ®Google Scholar
• KAUR D, YANTIRI F, RAJAGOPALAN S et al.: Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 37(6):899-909.
   PubMed Web of Science ®Google Scholar
• BEN-SHACHAR D, ESHEL G, FINBERG JP, YOUDIM MB: The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. (1991) 56(4):1441-1444.
   PubMed Web of Science ®Google Scholar
• GAL S, ZHENG H, FRIDKIN M, YOUDIM MB: Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. (2005) 95(1):79-88.
   PubMed Web of Science ®Google Scholar
• AVRAMOVICH-TIROSH Y, AMIT T, BAR-AM O et al.: Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem. (2007) 100(2):490-502.
   PubMed Web of Science ®Google Scholar
• MARUYAMA W, TAKAHASHI T, YOUDIM MBH, NAOI M: The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. (2002) 109(4):467-481.
   PubMed Web of Science ®Google Scholar
• YOUDIM MB, BAR AM O, YOGEV-FALACH M et al.: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. (2005) 79(1-2):172-179.
   PubMed Web of Science ®Google Scholar
• AKAO Y, MARUYAMA W, YI H et al.: An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. (2002) 326(2):105-108.
   PubMed Web of Science ®Google Scholar
• YOUDIM MB, AMIT T, BAR-AM O, WEINREB O, YOGEV-FALACH M: Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective–neurorescue drugs; ladostigil. Neurotox. Res. (2006) 10(3-4):181-192.
   PubMed Web of Science ®Google Scholar
• MARUYAMA W, WEINSTOCK M, YOUDIM MBH, NAGAI Y, NAOI M: Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. (2003) 341(3):233-236.
   PubMed Web of Science ®Google Scholar
• BAUM L, NG A: Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis. (2004) 6(4):367-377; discussion 443-449.
   PubMed Web of Science ®Google Scholar
• GUO Q, ZHAO B, LI M, SHEN S, XIN W: Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim. Biophys. Acta (1996) 1304(3):210-222.
   PubMed Web of Science ®Google Scholar
• JIAO Y, WILKINSON JT, CHRISTINE PIETSCH E et al.: Iron chelation in the biological activity of curcumin. Free Radic. Biol. Med. (2006) 40(7):1152-1160.
   PubMed Web of Science ®Google Scholar
• KUMAMOTO M, SONDA T, NAGAYAMA K, TABATA M: Effects of pH and metal ions on antioxidative activities of catechins. Biosci. Biotechnol. Biochem. (2001) 65(1):126-132.
   PubMed Web of Science ®Google Scholar
• DAI Q, BORENSTEIN AR, WU Y, JACKSON JC, LARSON EB: Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Am. J. Med. (2006) 119(9):751-759.
   PubMed Web of Science ®Google Scholar
• EHRNHOEFER DE, DUENNWALD M, MARKOVIC P et al.: Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. (2006) 15(18):2743-2751.
   PubMed Web of Science ®Google Scholar
• JOSEPH JA, SHUKITT-HALE B, CASADESUS G: Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. Am. J. Clin. Nutr. (2005) 81(1 Suppl.):S313-S316.
   PubMed Web of Science ®Google Scholar
• MAHER P, AKAISHI T, ABE K: Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc. Natl. Acad. Sci. USA (2006) 103(44):16568-16573.
   PubMed Web of Science ®Google Scholar
• MANDEL SA, AVRAMOVICH-TIROSH Y, REZNICHENKO L et al.: Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals (2005) 14(1-2):46-60.
   PubMed Web of Science ®Google Scholar
• WANG ZY, HUANG MT, LOU YR et al.: Inhibitory effects of black tea, green tea, decaffeinated black tea, and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7,12-dimethylbenz[a]anthracene-initiated SKH-1 mice. Cancer Res. (1994) 54(13):3428-3455.
   PubMed Web of Science ®Google Scholar
• YANG CS, WANG ZY: Tea and cancer. J. Natl. Cancer Inst. (1993) 85(13):1038-1049.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND BA, RAHMAN RM, APPLETON I: Mechanisms of action of green tea catechins, with a focus on ischemia-induced neurodegeneration. J. Nutr. Biochem. (2006) 17(5):291-306.
   PubMed Web of Science ®Google Scholar
• AKTAS O, PROZOROVSKI T, SMORODCHENKO A et al.: Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. (2004) 173(9):5794-5800.
   PubMed Web of Science ®Google Scholar
• LEVITES Y, WEINREB O, MAOR G, YOUDIM MBH, MANDEL S: Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. (2001) 78:1073-1082.
   PubMed Web of Science ®Google Scholar
• REZAI-ZADEH K, SHYTLE D, SUN N et al.: Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. (2005) 25(38):8807-8814.
   PubMed Web of Science ®Google Scholar
• CHECKOWAY H, POWERS K, SMITH-WELLER T et al.: Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol. (2002) 155(8):732-738.
   PubMed Web of Science ®Google Scholar
• LI SC, SCHOENBERG BS, WANG CC et al.: A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch. Neurol. (1985) 42(7):655-657.
   PubMed Web of Science ®Google Scholar
• ZHANG ZX, ROMAN GC: Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology (1993) 12(4):195-208.
   PubMed Web of Science ®Google Scholar
• KURIYAMA S, HOZAWA A, OHMORI K et al.: Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am. J. Clin. Nutr. (2006) 83(2):355-361.
   PubMed Web of Science ®Google Scholar
• RITCHIE K, LOVESTONE S: The dementias. Lancet (2002) 360(9347):1759-1766.
   PubMed Web of Science ®Google Scholar
• RINGMAN JM, FRAUTSCHY SA, COLE GM, MASTERMAN DL, CUMMINGS JL: A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer Res. (2005) 2(2):131-136.
   PubMedGoogle Scholar
• SCHROETER H, BOYD C, SPENCER JP et al.: MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide. Neurobiol. Aging (2002) 23(5):861-880.
   PubMed Web of Science ®Google Scholar
• REZNICHENKO L, AMIT T, YOUDIM MB, MANDEL S: Green tea polyphenol (-)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. J. Neurochem. (2005) 93(5):1157-1167.
   PubMed Web of Science ®Google Scholar
• LEVITES Y, AMIT T, YOUDIM MBH, MANDEL S: Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin-3-gallate neuroprotective action. J. Biol. Chem. (2002) 277(34):30574-30580.
   PubMed Web of Science ®Google Scholar
• WEINREB O, MANDEL S, YOUDIM MBH: cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J. (2003) 17(8):935-937.
   PubMed Web of Science ®Google Scholar
• KALFON L, YOUDIM MB, MANDEL SA: Green tea polyphenol (-)-epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection. J. Neurochem. (2007) 100(4):992-1002.
   PubMed Web of Science ®Google Scholar
• HIGDON JV, FREI B: Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit. Rev. Food Sci. Nutr. (2003) 43(1):89-143.
   PubMed Web of Science ®Google Scholar
• WISEMAN SA, BALENTINE DA, FREI B: Antioxidants in tea. Crit. Rev. Food Sci. Nutr. (1997) 37(8):705-718.
   PubMed Web of Science ®Google Scholar
• TOWNSEND PA, SCARABELLI TM, PASINI E et al.: Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB J. (2004) 18(13):1621-1623.
   PubMed Web of Science ®Google Scholar
• ZHOU YD, KIM YP, LI XC et al.: Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J. Nat. Prod. (2004) 67(12):2063-2069.
   PubMed Web of Science ®Google Scholar
• THOMAS R, KIM MH: Epigallocatechin gallate inhibits HIF-1α degradation in prostate cancer cells. Biochem. Biophys. Res. Commun. (2005) 334(2):543-548.
   PubMed Web of Science ®Google Scholar
• PAN T, FEI J, ZHOU X, JANKOVIC J, LE W: Effects of green tea polyphenols on dopamine uptake and on MPP+-induced dopamine neuron injury. Life Sci. (2003) 72(9):1073-1083.
   PubMed Web of Science ®Google Scholar
• LU H, MENG X, YANG CS: Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab. Dispos. (2003) 31(5):572-579.
   PubMed Web of Science ®Google Scholar
• LEVITES Y, AMIT T, MANDEL S, YOUDIM MBH: Neuroprotection and neurorescue against Aβ toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. (2003) 17(8):952-954.
   PubMed Web of Science ®Google Scholar
• REZNICHENKO L, AMIT T, ZHENG H et al.: Reduction of iron-regulated amyloid precursor protein and β-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J. Neurochem. (2006) 97(2):527-536.
   PubMed Web of Science ®Google Scholar
• KHAN N, AFAQ F, SALEEM M, AHMAD N, MUKHTAR H: Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. (2006) 66(5):2500-2505.
   PubMed Web of Science ®Google Scholar
• FRIEDLICH AL, TANZI RE, ROGERS JT: The 5′-untranslated region of Parkinson's disease α-synuclein messengerRNA contains a predicted iron responsive element. Mol. Psychiatry (2007) 12(3):222-223.
   PubMed Web of Science ®Google Scholar
• ROGERS JT, RANDALL JD, CAHILL CM et al.: An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. (2002) 277(47):45518-45528.
   PubMed Web of Science ®Google Scholar
• ZECCA L, YOUDIM MB, RIEDERER P, CONNOR JR, CRICHTON RR: Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. (2004) 5(11):863-873.
   PubMed Web of Science ®Google Scholar
• MANDEL S, MAOR G, YOUDIM MB: Iron and α-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J. Mol. Neurosci. (2004) 24(3):401-416.
   PubMed Web of Science ®Google Scholar
• KRAMER ML, SCHULZ-SCHAEFFER WJ: Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. (2007) 27(6):1405-1410.
   PubMed Web of Science ®Google Scholar
• BRAAK H, MULLER CM, RUB U et al.: Pathology associated with sporadic Parkinson's disease – where does it end? J. Neural Transm. Suppl. (2006) (70):89-97.
   PubMed Web of Science ®Google Scholar
• SULLIVAN PF, FAN C, PEROU CM: Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2006) 141(3):261-268.
   Web of Science ®Google Scholar
• BURCZYNSKI ME, DORNER AJ: Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics (2006) 7(2):187-202.
   PubMed Web of Science ®Google Scholar
• GLATT SJ, EVERALL IP, KREMEN WS et al.: Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc. Natl. Acad. Sci. USA (2005) 102(43):15533-15538.
   PubMed Web of Science ®Google Scholar
• SCHERZER CR, EKLUND AC, MORSE LJ et al.: Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. USA (2007) 104(3):955-960.
   PubMed Web of Science ®Google Scholar
• WEINREB W, AMIT T, GRUNBLATT E et al.: Gene and protein expression profiling in Parkinson's disease: effect of neuroprotective drugs. In: Genomics, Proteomics and the Nervous System. Handbook of Neurochemistry and Molecular Neurobiology (Volume 25). Lajtha A (Ed.), Springer, New York (2007).
   Google Scholar